Citations

Showing 10 of 108119 citations.

Possible Benefit and Validity of Supplements for Alcohol Use Disorder
Kang, Seungwoo , Choi, Doo‐Sup , Choi, Doo-Sup

Mayo Clinic

Alcoholism: Clinical and Experimental Research | February 26, 2019 | Volume: 43 | Issue: 5 | Pages: 780-782

10.1111/acer.13990 | PMID 30802317 Get It

Fate of the Fontan connection: Mechanisms of stenosis and management
Hagler, Donald J. , Miranda, William R. , Haggerty, Brielle J., Johnson, Jonathan N. , Cetta, Frank , Said, Sameh M. , Taggart, Nathaniel W. , Anderson, Jason H. , Johnson, Jonathan , Taggart, Nathaniel W

Mayo Clinic

Congenital Heart Disease | February 26, 2019 | Volume: 14 | Issue: 4 | Pages: 571-581

10.1111/chd.12757 | PMID 30801968 Get It

Is there a role for fetoscopic laser ablation therapy in Type‐2 vasa previa?
Ibirogba, Eniola R. , Shazly, Sherif A. , Chmait, Ramen H. , Ruano, Rodrigo , Shazly, S A , Chmait, R H , Ruano, Rodrigo , Ibirogba, Eniola R

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | February 26, 2019 | Volume: 54 | Issue: 5 | Pages: 696-696

10.1002/uog.20251 | PMID 30801796 Get It

Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer
Shah, Sagar , Schiapparelli, Paula , Vazquez-Ramos, Carla , Ruiz‐Valls, Alejandro , Inman, Kyle, Shamul, James G., Green, Jordan J. , Quiñones‐Hinojosa, Alfredo , Shah, Sagar R , Vazquez-Ramos, Carla A, Green, Jordan J , Kim, Jayoung , Martinez-Gutierrez, Juan Carlos , Inman, Kyle W

Mayo Clinic

Molecular Pharmaceutics | February 26, 2019 | Volume: 16 | Issue: 4 | Pages: 1433-1443

10.1021/acs.molpharmaceut.8b00959 | PMID 30803231 Get It

NKAP Must Associate with HDAC3 to Regulate Hematopoietic Stem Cell Maintenance and Survival
Shapiro, Michael J. , Lehrke, Michael Jonathan , Chung, Ji Young, Arocha, Sinibaldo Romero , Shapiro, Virginia Smith , Shapiro, Michael Jeremy , Romero Arocha, Sinibaldo, Shapiro, Virginia S , Lehrke, Michael J

Mayo Clinic

The Journal of Immunology | February 25, 2019 | Volume: 202 | Issue: 8 | Pages: 2287-2295

10.4049/jimmunol.1800862 | PMID 30804042 Get It

Abstract NKAP is a multifunctional nuclear protein that associates with the histone deacetylase HDAC3. Although both NKAP and HDAC3 are critical for hematopoietic stem cell (HSC) maintenance and survival, it was not known whether these two proteins work together. To assess the importance of their association in vivo, serial truncation and alanine scanning was performed on NKAP to identify the minimal binding site for HDAC3. Mutation of either Y352 or F347 to alanine abrogated the association of NKAP with HDAC3, but did not alter NKAP localization or expression. Using a linked conditional deletion/re-expression system in vivo, we demonstrated that re-expression of the Y352A NKAP mutant failed to restore HSC maintenance and survival in mice when endogenous NKAP expression was eliminated using Mx1-cre and poly-IC, whereas re-expression of wild type NKAP maintained the HSC pool. However, Y352A NKAP did restore proliferation in murine embryonic fibroblasts when endogenous NKAP expression was eliminated using ER-cre and tamoxifen. Therefore, Y352 in NKAP is critical for association with HDAC3 and for HSC maintenance and survival but is not important for proliferation of murine embryonic fibroblasts, demonstrating that NKAP functions in different complexes in different cell types.
Return of an Intact Hook Test Result: Clinical Assessment of Biceps Tendon Integrity After Surgical Repair
Pallante, Graham D. , O’Driscoll, Shawn W. , Fitzsimmons, James S

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 25, 2019 | Volume: 7 | Issue: 2 | Pages: No page available

10.1177/2325967119827311 | PMID 30828583 Get It

Background: The hook test is a sensitive and specific tool that has been previously described for diagnosing distal biceps tendon ruptures in an efficient, cost-effective manner. However, its application in postoperative evaluations after surgical repair of distal biceps tendon ruptures is not documented. Hypothesis/Purpose: We hypothesized that the hook test result returns to normal at some point postoperatively after distal biceps repair. This information could be used in decision making during follow-up examinations with both normal and abnormal findings. Study Design: Cohort study (diagnosis); Level of evidence, 3. Methods: We retrospectively reviewed records of distal biceps repair. Between July 1, 2003, and July 1, 2016, a total of 56 patients underwent distal biceps repair and also had clear documentation of the results of the hook test during the postoperative period. Hook test results consisted of “intact,” “abnormal,” or “absent.” The timing of the return to a normal hook test result was recorded. Results: Overall, 51 of 57 (89%) repairs were documented to have the hook test result return to “intact.” The test result returned to intact by a mean of 10 weeks after surgery (range, 2 weeks to 15 months). The biceps tendon was intact according to the hook test at the 4-month follow-up in 45 of the 51 patients (88%) in whom it ultimately returned. The hook test result was abnormal in 5 repairs in 5 patients with only a short-term follow-up, ranging from 2 to 7 weeks postoperatively. One patient with an abnormal hook test result at 2 weeks postoperatively underwent revision and was confirmed to have a partial tear of the biceps insertion. His hook test result returned to intact 3 months after revision repair. Conclusion: The hook test result returns to normal in patients who undergo distal biceps repair in the primary and revision settings with adequate follow-up. The vast majority of patients have a normal hook test result by 4 months postoperatively. An abnormal hook test result at 4 months postoperatively may indicate a failed repair and should prompt further investigation.
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Bekaii‐Saab, Tanios , Ahn, Daniel H. , Mortazavi, Amir , Lustberg, Maryam B. , Ramaswamy, Bhuvaneswari , Fowler, Jeffrey M., Wei, Lai , Overholser, Jay , Kaumaya, Pravin T. P. , Wei, Lai , Bekaii-Saab, Tanios S , Wesolowski, Robert , Wu, Christina , Lustberg, Maryam

Mayo Clinic

Clinical Cancer Research | February 25, 2019 | Volume: 25 | Issue: 12 | Pages: 3495-3507

10.1158/1078-0432.ccr-18-3997 | PMID 30804020 Get It

Abstract Purpose: This first-in-human phase I study (NCT 01417546) evaluated the safety profile, optimal immunologic/biological dose (OID/OBD), and immunogenicity of the combination of two peptide B-cell epitope vaccines engineered to represent the trastuzumab- and pertuzumab-binding sites. Although trastuzumab and pertuzumab have been approved for clinical use, patients often develop resistance to these therapies. We have advanced a new paradigm in immunotherapy that focuses on humoral responses based on conformational B-cell epitope vaccines. Patients and Methods: The vaccine is comprised of two chimeric HER-2 B-cell peptide vaccines incorporating a “promiscuous T-cell epitope.” Patients were immunized with the vaccine constructs emulsified with nor-muramyl-dipeptide adjuvant in a water-in-oil Montanide ISA 720VG vehicle. Eligible patients with metastatic and/or recurrent solid tumors received three inoculations every 3 weeks. Results: Forty-nine patients with a median of 4 prior lines of chemotherapy received at least 1 vaccination. Twenty-eight patients completed the 3 vaccination regimens. Six patients received 1 six-month boost after the regimen, and one patient received 7 six-month boosts. No serious adverse reactions or dose-limiting toxicities were observed. The vaccine was well tolerated with dose level 2 as the recommended phase II dose. The most common related toxicity in all patients was injection-site reactions (24%). Two patients had a partial response, 14 had stable disease, and 19 had progressive disease. Conclusions: The study vaccine is safe, exhibits antitumor activity, and shows preliminary indication that peptide vaccination may avoid therapeutic resistance and offer a promising alternative to monoclonal antibody therapies.
Thunderclap Headache and Cerebral Vasoconstriction Secondary to Pheochromocytoma
English, Stephen , Nasr, Deena M. , English, Stephen W

Mayo Clinic

JAMA Neurology | February 25, 2019 | Volume: 76 | Issue: 4 | Pages: 502

10.1001/jamaneurol.2019.0001 | PMID 30801609 Get It

Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G 0 /G 1 switch gene 2 (G0S2)
Xie, Xitao, Heckmann, Bradlee L. , Saarinen, Alicia M., Gu, Haiwei , Liu, Jun , Liu, Jun , Zhang, Xiaodong , Zechner, Rudolf , Liu, Jun

Mayo Clinic

The FASEB Journal | February 25, 2019 | Volume: 33 | Issue: 5 | Pages: 6655-6666

10.1096/fj.201802502r | PMID 30802154 Get It

ABSTRACT G 0 /G 1 switch gene 2 (G0S2) is a specific inhibitor of adipose triglyceride lipase (ATGL), the rate‐limiting enzyme for intracellular lipolysis. Recent studies show that G0S2 plays a critical role in promoting triacylglycerol (TG) accumulation in the liver, and its encoding gene is a direct target of a major lipogenic transcription factor liver X receptor (LXR)α. Here we sought to investigate a lipolysis‐independent role of G0S2 in hepatic triglyceride synthesis. Knockdown of G0S2 decreased hepatic TG content in mice with ATGL ablation. Conversely, overexpression of G0S2 promoted fatty acid incorporation into TGs and diacylglycerols in both wild‐type and ATGL‐deficient hepatocytes. Biochemical characterization showed that G0S2 mediates phosphatidic acid synthesis from lysophosphatidic acid (LPA) and acyl‐coenzyme A. In response to a high‐sucrose lipogenic diet, G0S2 is up‐regulated via LXRα and required for the increased TG accumulation in liver. Furthermore, deletion of a distinct 4‐aa motif necessary for the LPA‐specific acyltransferase (LPAAT) activity impaired G0S2's ability to mediate TG synthesis both in vitro and in vivo . These studies identify G0S2 as a dual‐function regulator of lipid metabolism as well as a novel mechanism whereby hepatic TG storage is promoted in response to lipogenic stimulation. In addition to its role as a lipolytic inhibitor, G0S2 is capable of directly promoting TG synthesis by acting as a lipid‐synthesizing enzyme.—Zhang, X., Xie, X., Heckmann, B. L., Saarinen, A. M., Gu, H., Zechner, R., Liu, J. Identification of an intrinsic lysophosphatidic acid acyltransferase activity in the lipolytic inhibitor G 0 /G 1 switch gene 2 (G0S2). FASEB J. 33, 6655–6666 (2019). www.fasebj.org
Direct repression of anoctamin 1 ( ANO1 ) gene transcription by Gli proteins
Mazzone, Amelia , Eisenman, Seth T., Strege, Peter R. , Zheng, Tenghao , D’Amato, Mauro , Ördög, Tamás , Fernández-Zapico, Martín E. , Farrugia, And Gianrico, Gibbons, Simon J. , D'Amato, Mauro , Zheng, Tenghao , Strege, Peter R , Mazzone, Amelia

Mayo Clinic

The FASEB Journal | February 25, 2019 | Volume: 33 | Issue: 5 | Pages: 6632-6642

10.1096/fj.201802373r | PMID 30802137 Get It

ABSTRACT The Ca 2+ ‐activated Cl − channel, anoctamin 1 (Ano1, also known as transmembrane protein 16A) contributes to intestinal pacemaking, fluid secretion, cellular excitability, and tissue development. The human ANO1 promoter contains binding sites for the glioma‐associated oncogene (Gli) proteins. We investigated regulation of ANO1 transcription by Gli. ANO1 promoter activity was determined using a luciferase reporter system. Binding and functional effects of Glis on ANO1 transcription and expression were demonstrated by chromatin immunoprecipitation, small interfering RNA knockdown, PCR, immunolabeling, and recordings of Ca 2+ ‐activated Cl − currents in human embryonic kidney 293 (HEK293) cells. Results from previous genome‐wide association studies were used to test ANO1 promoter polymorphisms for association with disease. Gli1 and Gli2 bound to the promoter and repressed ANO1 transcription. Repression depended on Gli binding to a site close to the ANO1 transcriptional start site. Mutation of this site prevented Gli binding and transcriptional repression. Knockdown of Gli expression and inhibition of Gli activity increased expression of ANO1 RNA and Ca 2+ ‐activated Cl − currents in HEK293 cells. A single‐nucleotide polymorphism prevented Gli binding and showed association with irritable bowel syndrome. We conclude that Gli1 and Gli2 repress ANO1 by a novel mechanism that is independent of Gli cleavage and that has a role in gastrointestinal function.—Mazzone, A., Gibbons, S. J., Eisenman, S. T., Strege, P. R., Zheng, T., D'Amato, M., Ordog, T., Fernandez‐Zapico, M. E., Farrugia, G. Direct repression of anoctamin 1 (ANO1) gene transcription by Gli proteins. FASEB J. 33, 6632–6642 (2019). www.fasebj.org